AH-008 Achieves Dual Regulatory Milestones with U.S. FDA IND Clearance and Taiwan CDE Index Case Designation for CIPN Prevention
Key Insights
AnHorn Medicines (search)' lead neuroprotective candidate AH-008 (search) received U.S. FDA IND clearance and Taiwan CDE Index Case designation for preventing chemotherapy-induced peripheral neuropathy (search) (CIPN).
CIPN is a common, dose-limiting toxicity of widely used chemotherapies including taxanes, platinum-based agents, vinca alkaloids, and ADCs, with no approved preventive therapies currently available.
Preclinical studies designed per FDA's January 2025 draft guidance showed AH-008 (search) preserved peripheral nerve integrity across multiple chemotherapy-induced neuropathy models without compromising chemotherapy efficacy.
AnHorn Medicines (search) today announced that its lead neuroprotective candidate AH-008 (search) has achieved two major regulatory milestones: Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (search) (FDA) and Index Case designation by the Taiwan Center for Drug Evaluation (search) (CDE). AH-008 is being developed as a first-in-class preventive therapy for chemotherapy-induced peripheral neuropathy (search) (CIPN), a condition for which no approved preventive therapies currently exist.
The dual milestones validate the scientific and translational strategy behind AH-008 (search) and mark a significant step toward advancing the candidate into clinical development.
A Critical Unmet Need in Oncology Supportive Care
Chemotherapy-induced peripheral neuropathy (search) is one of the most common and dose-limiting toxicities associated with widely used cancer treatments, including taxanes, platinum-based agents, vinca alkaloids, and antibody-drug conjugates (ADCs). The condition can cause irreversible nerve damage, leading to pain, sensory dysfunction, and long-term impairment that severely impacts patients' quality of life.
Beyond patient suffering, CIPN often forces chemotherapy dose reductions, treatment delays, or discontinuation — compromising cancer treatment outcomes. Despite its prevalence and burden, no approved therapies currently exist to prevent CIPN, highlighting a major unmet need in oncology supportive care.
Regulatory Validation Across Two Agencies
The U.S. FDA IND clearance authorizes AH-008 (search) to advance into human clinical trials, following a comprehensive review of its preclinical pharmacology, toxicology, and manufacturing data. This clearance affirms the robustness of the program's safety package and development strategy.
The Taiwan CDE Index Case designation recognizes AH-008 (search) as a reference program for novel drug development in its category. This designation reflects the candidate's scientific innovation and potential to address an unmet clinical need, while facilitating efficient regulatory interaction and advancement of innovative therapies.
Together, these milestones demonstrate strong regulatory alignment across major agencies and reinforce the translational strength of the AH-008 (search) program.
Preclinical Foundation Aligned with FDA Guidance
Preclinical studies for AH-008 (search) were designed in accordance with the U.S. FDA Draft Guidance issued in January 2025, titled "Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy (search): Developing Drug and Biological Products in Oncology." This guidance outlines FDA expectations for CIPN preventive therapies, emphasizing the use of clinically relevant neurotoxicity models and translational endpoints that connect nerve protection to meaningful functional outcomes.
AH-008 (search) consistently demonstrated robust neuroprotective effects across multiple chemotherapy-induced neuropathy models, preserving peripheral nerve integrity while maintaining chemotherapy efficacy. These prevention-first studies were designed to halt the onset of neuropathy rather than treating established symptoms, underscoring AH-008's potential as a proactive therapeutic approach.
Rapid Translation from Preclinical to IND
AnHorn Medicines (search) advanced AH-008 (search) from preclinical stage to FDA IND clearance in just 12 months, underscoring the company's integrated development capabilities. This accelerated timeline reflects AnHorn's ability to unify translational science, regulatory strategy, and CMC development into a streamlined execution framework.
About AH-008 (search) and AnHorn Medicines (search)
AH-008 (search) is a first-in-class neuroprotective therapeutic candidate designed to prevent chemotherapy-induced peripheral neuropathy (search) by targeting the underlying mechanisms of chemotherapy-related nerve damage. Unlike symptomatic treatments, AH-008 intervenes early in the disease cascade to preserve peripheral nerve function during cancer therapy.
Founded in 2020, AnHorn Medicines (search) is an AI-driven biotech company specializing in novel small molecules and protein degraders for aesthetic medicine, oncology, and cancer supportive care. The company's proprietary AIMCADD AI platform integrates generative AI and molecular simulation to design highly potent, safe, and patentable drug candidates.